4-(溴甲基)苯磺酸钠盐 | 32014-22-5

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 环羧酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(溴甲基)苯磺酸钠盐
• 中文别名: 对溴甲基苯磺酸钠
• 英文名称: sodium 4-bromomethylbenzenesulfonate
• 英文别名: Benzenesulfonic acid, 4-(bromomethyl)-, sodium salt；sodium;4-(bromomethyl)benzenesulfonate
• CAS: 32014-22-5
• 化学式: C₇H₆BrO₃S*Na
• 分子量: 273.083
• InChiKey: VUIRTEIRZXTTPR-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.51
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2904909090

反应信息

• 作为反应物：
  描述：

  4-(溴甲基)苯磺酸钠盐 在 吡啶 作用下， 反应 11.0h， 生成 trans-2-[2-(2,3,5,6,8,9,11,12-octahydro-1,4,7,10,13-pentaoxabenzocyclopentadecyn-16-yl)ethenyl]-3-(4-sulfobenzyl)benzothiazolium betaine
  参考文献：
  名称：

  Crown ether styryl dyes

  摘要：

  Novel styryl dyes (trans-2a,b) containing a 15-crown-5 ether moiety and an N-sulfobenzyl spacer were synthesized. The reactions of trans-2a,b with Mg(ClO4)(2) in MeCN afford dimeric complexes. During photolysis of the latter, trans-cis isomerization to give anion-"capped" complexes (cis-2a,b). Mg2+ and stereospecific [2+2] autocycloaddition to yield cyclobutane derivative occur in parallel. The ratio of the two transformation pathways of dyes 2a,b depends on the spacer type. To interpret the experimental data, the molecular-mechanics and semiempirical quantum-chemical calculations were performed.

  DOI：

  10.1007/bf02495515
• 作为产物：
  描述：

  4-(氨基甲基)苯磺酸 在 氢溴酸 、 sodium acetate 、 溶剂黄146 、 sodium nitrite 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 49.0h， 生成 4-(溴甲基)苯磺酸钠盐
  参考文献：
  名称：

  Hubbuch, Arnulf; Bindewald, Roland; Foehles, Josef, Angewandte Chemie, 1980, vol. 92, # 5, p. 394 - 395

  摘要：

  DOI：

文献信息

• Bitopic fluorescent antagonists of the A_2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners
  作者：Romain Duroux、Antonella Ciancetta、Philip Mannes、Jinha Yu、Shireesha Boyapati、Elizabeth Gizewski、Said Yous、Francisco Ciruela、John A. Auchampach、Zhan-Guo Gao、Kenneth A. Jacobson

  DOI：10.1039/c7md00247e

  日期：——

  Functionalized antagonist probes of the A_2A adenosine receptor.

  A_2A腺苷受体的功能化拮抗探针。
• [EN] HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES HETERO BIARYLE INHIBITEURS DE LA METALLOPROTEASE MATRICIELLE
  申请人：WARNER LAMBERT CO

  公开号：WO2004014366A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein Rl, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a' pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a' compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency,,inflammatory bowel, disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically, acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active, component as described in the specification.

  该发明提供了由式I定义或其药用盐组成的化合物，其中R1、Q、S、T、U、V和R2如规范中所定义。该发明还提供了包括式I的化合物或其药用盐以及药用载体、稀释剂或赋形剂的药物组合物，如规范中所定义。该发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予式I的化合物或其药用盐。该发明还提供了治疗患有MMP-13酶介导疾病的患者的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、非骨关节炎或类风湿性关节炎的关节炎、心力衰竭、炎性肠病、心力衰竭、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、牛皮癣、动脉粥样硬化和骨质疏松症的方法，包括向患者体内给予式I的化合物或其药用盐，单独或与药物组合使用。该发明还提供了组合物，包括式I的化合物或其药用盐，以及规范中描述的另一种药用活性成分。
• Fluorinated aniline derivatives and their use
  申请人：Boehringer Mannheim GmbH

  公开号：US04912258A1

  公开（公告）日：1990-03-27

  Fluorinated aniline derivatives of the general formula I are described ##STR1## in which R.sup.1 represents H or (CH.sub.2).sub.n -X, n is a whole number from 1 to 3, X is H, OH, NH.sub.2, CH.sub.3 CONH, CH.sub.3 SO.sub.2 NH, SO.sub.3 H or ArSO.sub.3 H, Ar is optionally substituted arylene radical, R.sup.1 is alternatively also a --(CH.sub.2).sub.3 -- group, which is bonded to the free o-position next to the N-atom, Y is H, --O--, --NH--, --S-- or a C--C single bond, R.sup.2, in the event that Y=H, is the same as or different from R.sup.1 and means one of the radicals shown for R.sup.1, and in the event that Y is a C--C single bond or --O--, --NH-- or --S--, is an alkylene group having 1 to 3 carbon atoms linked with Y, and R.sup.3 =H, alkyl having 1 to 3 carbon atoms, OCH.sub.3, CH.sub.3 CONH, CO.sub.2 H or SO.sub.3 H. The compounds of formula I form as coupling components together with the conventional color couplers a very sensitive chromogenic system which is suitable for the analytical determination of oxidizing substances, for example for the determination of H.sub.2 O.sub.2 and POD in body fluids.

  通式I的氟化苯胺衍生物描述如下：其中R.sup.1代表H或(CH.sub.2).sub.n -X，n是1到3之间的整数，X是H、OH、NH.sub.2、CH.sub.3 CONH、CH.sub.3 SO.sub.2 NH、SO.sub.3 H或ArSO.sub.3 H，Ar是可选取代的芳基基团，R.sup.1也可以是与N原子旁边的自由o-位置结合的--(CH.sub.2).sub.3--基团，Y是H、--O--、--NH--、--S--或C--C单键，如果Y=H，则R.sup.2与R.sup.1相同或不同，并表示R.sup.1所示的基团之一，如果Y是C--C单键或--O--、--NH--或--S--，则R.sup.2是与Y连接的具有1到3个碳原子的烷基基团，R.sup.3=H、具有1到3个碳原子的烷基、OCH.sub.3、CH.sub.3 CONH、CO.sub.2 H或SO.sub.3 H。通式I的化合物与传统的显色偶联剂一起形成了非常敏感的色素系统，适用于氧化物质的分析测定，例如用于体液中H.sub.2 O.sub.2和POD的测定。
• 一种移动终端、壳组件、电致变色材料及其制备方法
  申请人：宁波祢若电子科技有限公司

  公开号：CN111362867B

  公开（公告）日：2023-04-18

  本发明涉及一种电致变色材料，所述电致变色材料为包含阴极电致变色功能的官能基团和包含阳极电致变色功能的官能基团组成的离子对化合物，所述离子对化合物具有式(I)化学结构通式；其中，所述阴极电致变色功能的官能基团为全氟烷基和羟基改性后的联吡啶盐，所述阳极电致变色功能的官能基团为苯并三唑衍生物和双苯磺酸基团改性的吩嗪衍生物。本发明的电致变色材料具有耐老化、响应速度快、对比度高的优点。本发明还公开了一种包括上述电致变色材料的壳组件及移动终端，满足移动终端外观整体性要求，具有巨大的市场应用前景。
• [EN] ANTIVIRAL TREATMENT<br/>[FR] TRAITEMENT ANTIVIRAL
  申请人：ECOSYNTH NV

  公开号：WO2021176010A1

  公开（公告）日：2021-09-10

  The present description relates to the use of myramistin, its derivatives and the forms thereof for treating or ameliorating infections caused by enveloped viruses, methods for preparing the compounds and pharmaceutical compositions containing such compounds. In particular the use of myramistin, its derivatives and forms for treating or ameliorating infections caused by coronaviruses. More particularly, the present description relates to the use of myramistin, its derivatives and forms thereof for treating or ameliorating Coronavirus disease 2019 (COVID-19).

  本描述涉及使用肥皂草碱、其衍生物及其形式用于治疗或改善由包膜病毒引起的感染，制备这些化合物的方法以及含有这些化合物的药物组合物。特别是使用肥皂草碱、其衍生物和形式来治疗或改善由冠状病毒引起的感染。更具体地，本描述涉及使用肥皂草碱、其衍生物及其形式来治疗或改善冠状病毒病2019（COVID-19）。